

## Breakthroughs and Achievements in Neurocognitive Research

**MAS Ahmed**

Queen's Hospital, United Kingdom

### Cognitive Neuroscience Market Value

It is our pleasure to welcome you to the Cognitive Neuroscience to be held in Barcelona, Spain from February 22-23, 2020.

The organizing committee is gearing up for an exciting and informative program on a variety of topics, poster presentations and various programs for participants from all over the world. Unsurpassed substantiation cure for Neurocognitive disorders clearly shows that the close association of families and careers in the care of their loved ones is key to improving early revealing of Vascular Dementia, renewal to a healthy weight and sustaining long term wellbeing.

This conference will increase knowledge, provide support, assist learning and allow to seek out applicable services and to develop the best environment to support recovery from these complex and devastating diseases.

Cognitive neuroscience is the scientific field that is concerned with the study of the biological processes and aspects that underlie cognition, with a specific focus on the neural connections in the brain which are involved in mental processes.

Neurocognitive disorders are characterized by decline from an attained level of cognitive functioning mainly when physical changes can be seen to have occurred in brain, such as after neurological and mental illness, drug use, or brain injury. Neurocognitive disorders (NCDs) are a category of conditions that include dementia, amnesia, Alzheimer's disease, Mild cognitive impairment, Attention deficit hyperactive disorder, Hallucinogen persisting perception disorder, cerebellar cognitive affective syndrome, post-operative cognitive dysfunction, HIV associated neurocognitive disorder.

Alzheimer's disease is the most common form of dementia accounting for 50% to 70% of all cases. It mostly occurs in the older people who are 65 years and above. Moreover, growing awareness level regarding its symptoms, such as partial dementia, is projected to boost the demand. Currently, there are an estimated 4 million individuals with dementia in the USA with more than 100 000 deaths annually. The global market for Alzheimer's disease reached \$10.2 billion in 2012. The market is expected to decrease to \$9.5 billion in 2017 for a CAGR of -1.5%.

The Alzheimer's Association funds independent investigators worldwide, they have awarded over \$335 million to more than 2,250 projects. The global cost of Alzheimer's and dementia is estimated to be \$605 billion, which is equivalent to 1% of the entire world's gross domestic product.

Aggregate Cost of Care by Payer for Americans Age 65 and Older with Alzheimer's Disease and Other Dementias: Medicare \$113 Billion, Medicaid \$41 Billion, Out of pocket \$44 Billion, Other \$29 Billion.

Dementia is widely considered the second most common cause of dementia after Alzheimer's disease, accounting for 10 percent of cases. Many experts believe that vascular dementia remains underdiagnosed like Alzheimer's disease even though it's recognized as common. The global market for treatments for syndromes of dementia and movement disorders was valued at 10.5 billion in 2011 and should reach \$11.1 billion in 2012. Total market value is expected to reach \$16.7 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 8.5%.